Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone
Hematologic malignancies and cancer patients who become neutropenic as a result of disease or myelosuppressive cytotoxic therapy are at a high risk of developing life-threatening infections, and hence empirical antibiotic therapy is administered promptly. We investigated once daily regimen of amikac...
Gespeichert in:
| Veröffentlicht in: | Journal of the Medical Association of Thailand 1993-06, Vol.76 (6), p.314-318 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 318 |
|---|---|
| container_issue | 6 |
| container_start_page | 314 |
| container_title | Journal of the Medical Association of Thailand |
| container_volume | 76 |
| creator | Suwangool, P Aswapokee, N Sathapatayavongs, B Leelasuphasri, S Siritanaratkul, N Chuncharunee, S Chayakul, P |
| description | Hematologic malignancies and cancer patients who become neutropenic as a result of disease or myelosuppressive cytotoxic therapy are at a high risk of developing life-threatening infections, and hence empirical antibiotic therapy is administered promptly. We investigated once daily regimen of amikacin, for dose-dependent bactericidal activity and post-antibiotic effects, plus ceftriaxone, with a long-half life to maximise time-dependent bactericidal activity. Microbiologically proven septicemia were 11 out of 49 febrile episodes (22.5%) and 10 (91%) of these were due to gram-negative bacilli, mostly Enterobacteriaceae. The overall success of the regimen was 63.3 per cent of patients, with no significant toxicity. In conclusion, our findings suggest that once-daily administration of amikacin plus ceftriaxone in the initial treatment of febrile episodes in neutropenic patients produces satisfactory results and more cost-effective compared with other antibiotic regimens requiring 3-4 doses a day. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_8083623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8083623</sourcerecordid><originalsourceid>FETCH-LOGICAL-p150t-e8b578e96a5ad4f6677727e3ea8b081040f9af9322c31cfa27cb9fdb61ba601a3</originalsourceid><addsrcrecordid>eNo9jztPwzAUhTOASin8BCQPrJH8SJxkRFV5SJVYYK6unWt6IXEs2xH03xOJiukM33noXBRrLmRdSsnbq-I6pU_Oq7rTalWsWt4qLdW6GHdjoEgWBgY-k6Epk2X5iBHCiZFnDk2kAZnHOccpoF9wgEzoc2LflI8skf8YsOyBhhPrp4QMRvoCu4TDMCdm0eVI8DN5vCkuHQwJb8-6Kd4fd2_b53L_-vSyfdiXQdQ8l9iaummx01BDXzmtm6aRDSqE1vBW8Iq7DlynpLRKWAeysaZzvdHCgOYC1Ka4--sNsxmxP4RII8TT4Xx74fdnDmm57iJ4S-nfVkmxjGj1C6xuYnw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Suwangool, P ; Aswapokee, N ; Sathapatayavongs, B ; Leelasuphasri, S ; Siritanaratkul, N ; Chuncharunee, S ; Chayakul, P</creator><creatorcontrib>Suwangool, P ; Aswapokee, N ; Sathapatayavongs, B ; Leelasuphasri, S ; Siritanaratkul, N ; Chuncharunee, S ; Chayakul, P</creatorcontrib><description>Hematologic malignancies and cancer patients who become neutropenic as a result of disease or myelosuppressive cytotoxic therapy are at a high risk of developing life-threatening infections, and hence empirical antibiotic therapy is administered promptly. We investigated once daily regimen of amikacin, for dose-dependent bactericidal activity and post-antibiotic effects, plus ceftriaxone, with a long-half life to maximise time-dependent bactericidal activity. Microbiologically proven septicemia were 11 out of 49 febrile episodes (22.5%) and 10 (91%) of these were due to gram-negative bacilli, mostly Enterobacteriaceae. The overall success of the regimen was 63.3 per cent of patients, with no significant toxicity. In conclusion, our findings suggest that once-daily administration of amikacin plus ceftriaxone in the initial treatment of febrile episodes in neutropenic patients produces satisfactory results and more cost-effective compared with other antibiotic regimens requiring 3-4 doses a day.</description><identifier>ISSN: 0125-2208</identifier><identifier>PMID: 8083623</identifier><identifier>CODEN: JMTHBU</identifier><language>eng</language><publisher>Bangkok: Medical Association of Thailand</publisher><subject>Adolescent ; Adult ; Aged ; Amikacin - administration & dosage ; Amikacin - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Ceftriaxone - administration & dosage ; Ceftriaxone - therapeutic use ; Drug Therapy, Combination - therapeutic use ; Female ; Fever of Unknown Origin - complications ; Fever of Unknown Origin - drug therapy ; Humans ; Male ; Medical sciences ; Middle Aged ; Neutropenia - complications ; Neutropenia - drug therapy ; Pharmacology. Drug treatments ; Sepsis - complications ; Sepsis - drug therapy ; Tropical medicine</subject><ispartof>Journal of the Medical Association of Thailand, 1993-06, Vol.76 (6), p.314-318</ispartof><rights>1994 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4211046$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8083623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suwangool, P</creatorcontrib><creatorcontrib>Aswapokee, N</creatorcontrib><creatorcontrib>Sathapatayavongs, B</creatorcontrib><creatorcontrib>Leelasuphasri, S</creatorcontrib><creatorcontrib>Siritanaratkul, N</creatorcontrib><creatorcontrib>Chuncharunee, S</creatorcontrib><creatorcontrib>Chayakul, P</creatorcontrib><title>Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone</title><title>Journal of the Medical Association of Thailand</title><addtitle>J Med Assoc Thai</addtitle><description>Hematologic malignancies and cancer patients who become neutropenic as a result of disease or myelosuppressive cytotoxic therapy are at a high risk of developing life-threatening infections, and hence empirical antibiotic therapy is administered promptly. We investigated once daily regimen of amikacin, for dose-dependent bactericidal activity and post-antibiotic effects, plus ceftriaxone, with a long-half life to maximise time-dependent bactericidal activity. Microbiologically proven septicemia were 11 out of 49 febrile episodes (22.5%) and 10 (91%) of these were due to gram-negative bacilli, mostly Enterobacteriaceae. The overall success of the regimen was 63.3 per cent of patients, with no significant toxicity. In conclusion, our findings suggest that once-daily administration of amikacin plus ceftriaxone in the initial treatment of febrile episodes in neutropenic patients produces satisfactory results and more cost-effective compared with other antibiotic regimens requiring 3-4 doses a day.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Amikacin - administration & dosage</subject><subject>Amikacin - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Ceftriaxone - administration & dosage</subject><subject>Ceftriaxone - therapeutic use</subject><subject>Drug Therapy, Combination - therapeutic use</subject><subject>Female</subject><subject>Fever of Unknown Origin - complications</subject><subject>Fever of Unknown Origin - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neutropenia - complications</subject><subject>Neutropenia - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Sepsis - complications</subject><subject>Sepsis - drug therapy</subject><subject>Tropical medicine</subject><issn>0125-2208</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9jztPwzAUhTOASin8BCQPrJH8SJxkRFV5SJVYYK6unWt6IXEs2xH03xOJiukM33noXBRrLmRdSsnbq-I6pU_Oq7rTalWsWt4qLdW6GHdjoEgWBgY-k6Epk2X5iBHCiZFnDk2kAZnHOccpoF9wgEzoc2LflI8skf8YsOyBhhPrp4QMRvoCu4TDMCdm0eVI8DN5vCkuHQwJb8-6Kd4fd2_b53L_-vSyfdiXQdQ8l9iaummx01BDXzmtm6aRDSqE1vBW8Iq7DlynpLRKWAeysaZzvdHCgOYC1Ka4--sNsxmxP4RII8TT4Xx74fdnDmm57iJ4S-nfVkmxjGj1C6xuYnw</recordid><startdate>199306</startdate><enddate>199306</enddate><creator>Suwangool, P</creator><creator>Aswapokee, N</creator><creator>Sathapatayavongs, B</creator><creator>Leelasuphasri, S</creator><creator>Siritanaratkul, N</creator><creator>Chuncharunee, S</creator><creator>Chayakul, P</creator><general>Medical Association of Thailand</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>199306</creationdate><title>Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone</title><author>Suwangool, P ; Aswapokee, N ; Sathapatayavongs, B ; Leelasuphasri, S ; Siritanaratkul, N ; Chuncharunee, S ; Chayakul, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p150t-e8b578e96a5ad4f6677727e3ea8b081040f9af9322c31cfa27cb9fdb61ba601a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Amikacin - administration & dosage</topic><topic>Amikacin - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Ceftriaxone - administration & dosage</topic><topic>Ceftriaxone - therapeutic use</topic><topic>Drug Therapy, Combination - therapeutic use</topic><topic>Female</topic><topic>Fever of Unknown Origin - complications</topic><topic>Fever of Unknown Origin - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neutropenia - complications</topic><topic>Neutropenia - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Sepsis - complications</topic><topic>Sepsis - drug therapy</topic><topic>Tropical medicine</topic><toplevel>online_resources</toplevel><creatorcontrib>Suwangool, P</creatorcontrib><creatorcontrib>Aswapokee, N</creatorcontrib><creatorcontrib>Sathapatayavongs, B</creatorcontrib><creatorcontrib>Leelasuphasri, S</creatorcontrib><creatorcontrib>Siritanaratkul, N</creatorcontrib><creatorcontrib>Chuncharunee, S</creatorcontrib><creatorcontrib>Chayakul, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of the Medical Association of Thailand</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suwangool, P</au><au>Aswapokee, N</au><au>Sathapatayavongs, B</au><au>Leelasuphasri, S</au><au>Siritanaratkul, N</au><au>Chuncharunee, S</au><au>Chayakul, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone</atitle><jtitle>Journal of the Medical Association of Thailand</jtitle><addtitle>J Med Assoc Thai</addtitle><date>1993-06</date><risdate>1993</risdate><volume>76</volume><issue>6</issue><spage>314</spage><epage>318</epage><pages>314-318</pages><issn>0125-2208</issn><coden>JMTHBU</coden><abstract>Hematologic malignancies and cancer patients who become neutropenic as a result of disease or myelosuppressive cytotoxic therapy are at a high risk of developing life-threatening infections, and hence empirical antibiotic therapy is administered promptly. We investigated once daily regimen of amikacin, for dose-dependent bactericidal activity and post-antibiotic effects, plus ceftriaxone, with a long-half life to maximise time-dependent bactericidal activity. Microbiologically proven septicemia were 11 out of 49 febrile episodes (22.5%) and 10 (91%) of these were due to gram-negative bacilli, mostly Enterobacteriaceae. The overall success of the regimen was 63.3 per cent of patients, with no significant toxicity. In conclusion, our findings suggest that once-daily administration of amikacin plus ceftriaxone in the initial treatment of febrile episodes in neutropenic patients produces satisfactory results and more cost-effective compared with other antibiotic regimens requiring 3-4 doses a day.</abstract><cop>Bangkok</cop><pub>Medical Association of Thailand</pub><pmid>8083623</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0125-2208 |
| ispartof | Journal of the Medical Association of Thailand, 1993-06, Vol.76 (6), p.314-318 |
| issn | 0125-2208 |
| language | eng |
| recordid | cdi_pubmed_primary_8083623 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Amikacin - administration & dosage Amikacin - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Ceftriaxone - administration & dosage Ceftriaxone - therapeutic use Drug Therapy, Combination - therapeutic use Female Fever of Unknown Origin - complications Fever of Unknown Origin - drug therapy Humans Male Medical sciences Middle Aged Neutropenia - complications Neutropenia - drug therapy Pharmacology. Drug treatments Sepsis - complications Sepsis - drug therapy Tropical medicine |
| title | Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T07%3A33%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Empirical%20antibiotic%20therapy%20in%20febrile%20neutropenic%20patients%20with%20single-daily%20dose%20amikacin%20plus%20ceftriaxone&rft.jtitle=Journal%20of%20the%20Medical%20Association%20of%20Thailand&rft.au=Suwangool,%20P&rft.date=1993-06&rft.volume=76&rft.issue=6&rft.spage=314&rft.epage=318&rft.pages=314-318&rft.issn=0125-2208&rft.coden=JMTHBU&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E8083623%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8083623&rfr_iscdi=true |